NEW YORK, July 23, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
--
Pfizer Inc. Research Reports
On July 16, 2014, Pfizer Inc. (Pfizer) announced that it has entered into an agreement to acquire InnoPharma, Inc. (InnoPharma) for an upfront cash payment of $225 million, and up to $135 million of contingent milestone payments. Pfizer Global Established Pharma (GEP) Group President, John Young, said, "Today's announcement is an important milestone as we continue to look for innovative growth opportunities for our sterile injectables portfolio, which will increase to seventy three products with this acquisition. InnoPharma's technical capabilities in bringing complex generics to market, coupled with its strong talent and product pipeline, build on our efforts to develop and commercialize critically important medicines for the patients who need them." The full research reports on Pfizer are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/PFE/report.pdf
--
Gentiva Health Services Inc. Research Reports
On July 17, 2014, Gentiva Health Services Inc. (Gentiva) announced that its Board of Directors has unanimously determined to reject the partial tender offer from Kindred Healthcare, Inc. to acquire 14.9% of the outstanding shares of the Company for $16.00 per share in cash, upon careful consideration and consultation with the Company's legal and financial advisors. Gentiva informed that its Board determined that the offer significantly undervalues Company shares, is coercive and not in the best interests of its stockholders. Gentiva further stated that its Board has also received a proposal from a recognized owner, operator and investor in the sector to acquire all of the outstanding shares of the Company's common stock for $17.25 per share in cash, which the board will review carefully, in consultation with Company legal and financial advisors, in due course. Rod Windley, Gentiva Executive Chairman, said, "Regarding Kindred's amended partial Offer, the Board concluded based on thorough analysis that it still leaves a significant gap between the true value of Gentiva and the consideration being offered and is not in the best interests of Gentiva stockholders." The full research reports on Gentiva are available todownload free of charge at:
http://www.analystsreview.com/Jul-23-2014/GTIV/report.pdf
--
bluebird bio, Inc. Research Reports
On July 16, 2014, bluebird bio, Inc. (bluebird bio) announced that it has appointed Mark Vachon to its Board of Directors. Commenting on the appointment, Chief bluebird, Nick Leschly, stated, "We are delighted to welcome Mr. Vachon to our board. Mark's extensive global experience across healthcare in both general management and financial leadership positions will be invaluable to bluebird as we look to grow our business and potentially introduce innovative gene therapies to treat blood disorders, adrenoleukodystrophy and cancers." The full research reports onbluebird bio are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/BLUE/report.pdf
--
Agios Pharmaceuticals, Inc. Research Reports
On July 18, 2014, Agios Pharmaceuticals, Inc.'s stock increased by 11.83%, closing at $37.14 per share. Over the past three days the Company's stock dipped by 1.33% compared to the Nasdaq Composite which went up by 0.36% during the same period. The full research reportson Agios are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/AGIO/report.pdf
--
AcelRx Pharmaceuticals, Inc. Research Reports
On July 18, 2014, AcelRx Pharmaceuticals, Inc.'s stock reflected an increase of 11.68%, ending the day at $10.04 per share. In the past one month, the Company's stock slipped 10.12% compared to the Nasdaq Composite which increased by 1.52% during the same period. The fullresearch reports on AcelRx are available to download free of charge at:
http://www.analystsreview.com/Jul-23-2014/ACRX/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
